Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK....
+See More2018-11-15 12:35:00 Thursday ET
Warren Buffett approves Berkshire Hathaway to implement new meaningful stock repurchases. Buffett sends a positive signal to the stock market with the Berks
2018-11-25 12:37:00 Sunday ET
The Chinese administration delivers a written response to U.S. demands for trade reforms. This strategic move helps trigger more formal negotiations between
2019-07-31 11:34:00 Wednesday ET
AYA Analytica finbuzz podcast channel on YouTube July 2019 In this podcast, we discuss several topical issues as of July 2019: (1) All 18 systemical
2018-03-19 10:37:00 Monday ET
Uber's autonomous car causes the first known pedestrian fatality from a driverless vehicle and thus sets off the alarm bell for artificial intelligence.
2023-01-09 10:31:00 Monday ET
Response to USPTO fintech patent protection As of early-January 2023, the U.S. Patent and Trademark Office (USPTO) has approved our U.S. utility patent
2021-05-20 10:30:00 Thursday ET
Artificial intelligence, 5G, and virtual reality can help transform global trade, finance, and technology. Core trade technological advances and disruptive